Chemomab Therapeutics LTD

Neil Harris Cohen, a Director of Chemomab Therapeutics Ltd., sold 2,304 shares of common stock on August 27, 2026.

Chemomab Therapeutics CEO Adi Mor George reports transactions involving American Depositary Shares and Restricted Share Units.

HBM Healthcare Investments formally notified Chemomab Therapeutics Ltd. of its election to exercise pre-funded warrants, fulfilling obligations under a Shareholder Support Agreement.

Chemomab Therapeutics Ltd. shareholders, including HBM Healthcare Investments, have entered into a support agreement to vote in favor of the proposed merger with Scipher Medicine Corporation.

OrbiMed Israel BioFund GP Limited Partnership and its affiliates have filed an exit Schedule 13D/A, reporting a reduction in their beneficial ownership of Chemomab Therapeutics Ltd. to below 5% following a sale of 1.61 million ADSs.

Touchstone Global Investments Pty Ltd has increased its beneficial ownership of Chemomab Therapeutics Ltd. American Depositary Shares to 5.2%.

Erik Otto has filed a Schedule 13G, reporting beneficial ownership of 90,000 American Depository Shares in Chemomab Therapeutics Ltd., representing 1.2% of the class.

Erik Otto has reported a 6.3% beneficial ownership stake in Chemomab Therapeutics Ltd., holding 385,000 American Depository Shares.

Erik Otto has increased his beneficial ownership in Chemomab Therapeutics Ltd. to 8.1% of the outstanding American Depository Shares.

Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have reported ceasing to be beneficial owners of more than five percent of Chemomab Therapeutics Ltd.'s ordinary shares.

Morgan Stanley and its subsidiary have disclosed an 8.4% beneficial ownership stake in Chemomab Therapeutics Ltd. as of June 30, 2025.